Max Healthcare Seeks Approval for 73.5 Lakh PRSU Scheme

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Max Healthcare Seeks Approval for 73.5 Lakh PRSU Scheme

Max Healthcare Institute Ltd has issued a postal ballot seeking shareholder approval for a new Performance Linked Restricted Stock Unit Scheme covering 73.5 lakh PRSUs, revised remuneration terms for Chairman and Managing Director Abhay Soi, and amendments to its Memorandum of Association to enable future expansion into medical education, pharmaceuticals and hospital-related food services. The proposals will be decided through e-voting ending on October 19, 2026.

Max Healthcare Seeks Shareholder Approval for PRSU Scheme and Governance Proposals

Key Filing Number: 73.5 lakh Performance Linked Restricted Stock Units proposed.
Key Filing Number: E-voting from September 20, 2026 to October 19, 2026.

Reader Takeaway: Talent retention framework expands, but proposals await shareholder approval before taking effect.

What just happened

Max Healthcare Institute Ltd has issued a postal ballot notice seeking shareholder approval for multiple governance and strategic proposals.

The principal proposal is the introduction of the 'Max Healthcare Institute Limited – Performance Linked Restricted Stock Unit Scheme 2026', which creates a fresh pool of 73.5 lakh PRSUs, representing about 0.76% of the company's existing paid-up equity share capital.

The company stated that the scheme is intended to attract, motivate and retain employees by linking long-term incentives to company and individual performance.

Why this matters

Under the proposed scheme, vesting begins only after three years from the grant date, with subsequent vesting continuing up to the fifth anniversary, or the sixth anniversary in specified deferred cases.

Performance parameters include consolidated EBITDA, total shareholder return, clinical excellence metrics for medical professionals and performance goals for non-medical employees.

The company has also proposed shareholder approval for the remuneration of Chairman and Managing Director Abhay Soi for the period from June 19, 2026 to June 18, 2028.

The filing states that his fixed annual remuneration will remain unchanged at ₹28.17 crore, while the proportion of performance-linked variable remuneration will increase, subject to specified governance limits.

What changes now

The postal ballot also proposes amendments to the company's Memorandum of Association.

If approved, the changes will enable the company to undertake activities relating to medical education, pharmaceutical and radiopharmaceutical manufacturing, and food and beverage services associated with hospitals and other establishments.

The filing clarifies that these amendments are enabling provisions and do not represent an immediate investment or business expansion.

Risks to watch

  • Shareholder approval of all resolutions.
  • Implementation of the PRSU scheme.
  • Future use of the expanded business objects.
  • Long-term impact of equity-based employee incentives.

What to track next

Investors should monitor the postal ballot outcome, with e-voting scheduled from September 20 to October 19, 2026. The company expects to declare the voting results on or before October 22, 2026.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.